Draft guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission

  • Email
  • Help

Document details

Download document Draft guideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission
Reference number EMA/CHMP/BWP/187338/2014
Status draft: consultation closed
First published 2014-04-30
Last updated 2014-04-30

Summary

Guidance is provided on data requirements for process validation of biotechnology-derived proteins used as active substance in the manufacture of medicinal products. This guideline covers process evaluation and verification studies for the upstream and downstream process, in the context of a marketing authorisation application or a variation application if relevant.